Differences in innate immune response between man and mouse

Zschaler, Josefin; Schlorke, Denise; Arnhold, J

doi:10.1615/critrevimmunol.2014011600

Cited by 164 publications

(182 citation statements)

References 113 publications

Supporting

Mentioning

178

Contrasting

Unclassified

Order By: Relevance

“…As an example that is instructive for immunology, haematopoiesis in the mouse spleen is active into adulthood, whereas in humans, this ends before birth. [38][39][40] The use of splenic lymphocytes as is standard in preclinical research should be interpreted in this context. In the context of targeted therapy, it is important to know that targets such as fms-related tyrosine kinase-3 (flt-3) and toll-like receptors are distributed and regulated differently in mice compared with humans.…”

Section: Mice As Hosts-reasons For the "Translational Gap"mentioning

confidence: 99%

Tumour and normal tissue radiobiology in mouse models: how close are mice to mini-humans?

Koontz¹,

Verhaegen²,

Ruysscher³

2017

BJR

View full text Add to dashboard Cite

Animal modelling is essential to the study of radiobiology and the advancement of clinical radiation oncology by providing preclinical data. Mouse models in particular have been highly utilized in the study of both tumour and normal tissue radiobiology because of their cost effectiveness and versatility. Technology has significantly advanced in preclinical radiation techniques to allow highly conformal image-guided irradiation of small animals in an effort to mimic human treatment capabilities. However, the biological and physical limitations of animal modelling should be recognized and considered when interpreting preclinical radiotherapy (RT) studies. Murine tumour and normal tissue radioresponse has been shown to vary from human cellular and molecular pathways. Small animal irradiation techniques utilize different anatomical boundaries and may have different physical properties than human RT. This review addresses the difference between the human condition and mouse models and discusses possible strategies for future refinement of murine models of cancer and radiation for the benefit of both basic radiobiology and clinical translation.

show abstract

Section: Mice As Hosts-reasons For the "Translational Gap"mentioning

confidence: 99%

Tumour and normal tissue radiobiology in mouse models: how close are mice to mini-humans?

Koontz¹,

Verhaegen²,

Ruysscher³

2017

BJR

View full text Add to dashboard Cite

show abstract

“…aging, infection, metabolic syndrome) in rodents may provide a more relevant model of human POCD (87–89). Further, given the significant differences between the mouse and human immune systems and inflammatory mechanisms (90), it is unclear to what extent the neuroinflammatory mechanisms seen in mouse models are involved in human POCD.…”

Section: What Causes Pocd?mentioning

confidence: 99%

Postoperative Cognitive Dysfunction

Berger

Nadler

Browndyke

et al. 2015

Anesthesiology Clinics

227

119

View full text Add to dashboard Cite

Ever since Bedford’s seminal Lancet case series in 1955, we have known that perioperative care is sometimes followed by significant cognitive dysfunction (1). Although the safety of perioperative care has improved dramatically since 1955, the descriptions of cognitive dysfunction in that case series are eerily similar to the complaints of current patients suffering from post-operative cognitive dysfunction (POCD). POCD remains a common post-operative complication associated with significant morbidity and even mortality, especially among elderly patients. There has been a great deal of interest in and controversy about POCD, from how it is measured, to how long it lasts, to its precise implications for patients. This interest and controversy is reflected partly in the increasing number of papers published on this subject recently (shown in Figure 1). Recent work has also suggested surgery may be associated with cognitive improvement in some patients (2–4), termed Post-Operative Cognitive Improvement (POCI). As the number of surgeries performed worldwide approaches 250 million per year (5) (with an increasing number elderly patients), optimizing postoperative cognitive function and preventing/treating POCD are major public health issues. In this article we review the literature on POCD and POCI, and discuss current research challenges in this area.

show abstract

“…As such, the suppression of CCL11 release or inhibition of CCL11 with antibody therapies after ischemic stroke could represent an attractive therapeutic target to decrease age-related impairments in stroke recovery. However, the translation of successful experimental immunotherapies has failed in many clinical trials, due in part to profound differences in the immune system between species [10]. In order to determine the relevance of circulating CCL11 as a clinically relevant target, we examined circulating CCL11 levels in human stroke patients and controls.…”

Section: Introductionmentioning

confidence: 99%

CCL11 (Eotaxin-1) Levels Predict Long-Term Functional Outcomes in Patients Following Ischemic Stroke

Roy-O’Reilly

Ritzel

Conway

et al. 2017

Transl. Stroke Res.

View full text Add to dashboard Cite

Circulating levels of the pro-inflammatory cytokine C-C motif chemokine 11 (CCL11, also known as eotaxin-1) are increased in several animal models of neuroinflammation, including traumatic brain injury and Alzheimer’s disease. Increased levels of CCL11 have also been linked to decreased neurogenesis in mice. We hypothesized that circulating CCL11 levels would increase following ischemic stroke in mice and humans and that higher CCL11 levels would correlate with poor-long term recovery in patients. As predicted, circulating levels of CCL11 in both young and aged mice increased significantly 24 hours after experimental stroke. However, CCL11 levels were decreased in ischemic stroke patients compared to controls at 24 hours after stroke. Interestingly, lower post-stroke CCL11 levels were independently predictive of increased stroke severity and poorer functional outcomes in patients twelve months after ischemic stroke. These results illustrate the differences in the murine and human inflammatory response to ischemic stroke. In addition, it suggests CCL11 as a candidate biomarker for the prediction of acute and long-term functional outcomes in ischemic stroke patients.

show abstract

Differences in innate immune response between man and mouse

Cited by 164 publications

References 113 publications

Tumour and normal tissue radiobiology in mouse models: how close are mice to mini-humans?

Tumour and normal tissue radiobiology in mouse models: how close are mice to mini-humans?

Postoperative Cognitive Dysfunction

CCL11 (Eotaxin-1) Levels Predict Long-Term Functional Outcomes in Patients Following Ischemic Stroke

Contact Info

Product

Resources

About